Cell Immunol. 2026 Nov 04. pii: S0008-8749(26)00108-5. [Epub ahead of print]430
105167
Natural killer (NK) cells are innate lymphocytes that exert cytotoxic activity against malignant and virus-infected cells without prior antigen sensitization. Chimeric antigen receptor (CAR)-engineered NK (CAR-NK) cells combine CAR-dependent tumor-antigen recognition with endogenous NK-cell receptor-dependent cytotoxicity against stress-induced ligands and tumor cells with reduced HLA class I expression. Clinical studies of allogeneic CD19 CAR-NK cells have reported antitumor responses without notable cytokine release syndrome, neurotoxicity, or graft-versus-host disease. CAR-NK cells also support allogeneic manufacturing for off-the-shelf cellular therapy. NK-associated intracellular domains including DAP10, DAP12, 2B4, and CD3ζ, cytokine expression using IL-15 or IL-21, and gene editing of inhibitory molecules have been incorporated into CAR-NK designs. PI3K-AKT-mTORC1 and JAK-STAT signaling, glycolytic metabolism, mitochondrial activity, and transcriptional control contribute to CAR-NK cytotoxic function. Recent CAR-NK studies have also examined inhibitory-receptor editing, chemokine receptor expression, and metabolic engineering to improve cytotoxic activity, intratumoral infiltration, and resistance to hypoxia and immunosuppressive signaling in solid tumors. This review examines the molecular mechanisms involved in NK-cell activation and metabolism and evaluates molecular engineering strategies for next-generation CAR-NK therapy in solid tumors.
Keywords: CAR-NK cells; Cytokine engineering; Metabolic regulation; NK-specific signaling; Tumor microenvironment